Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Reports Third Quarter 2019 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  Today, November 14, 2019 , at 5:30 p.m. ET CELEBRATION, Fla. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary
Toggle Summary KemPharm to Report Third Quarter 2019 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, November 14, 2019 , 5:30 p.m. ET CELEBRATION, Fla. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019
KVK-Tech is Initially Stocking Selected Regions Based on Formulary Access CELEBRATION, Fla. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today provided a commercial update
Toggle Summary KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting
Data Demonstrate that KP415 Can Be Administered without Regard to Food; Can Be Mixed into Foods or Drink CELEBRATION, Fla. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,
Toggle Summary KemPharm Provides Updates Regarding its Board of Directors
CELEBRATION, Fla. , Sept. 20, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that, on September 18, 2019 , Danny L. Thompson provided notice of his resignation from the
Toggle Summary KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases
CELEBRATION, Fla. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C.
Toggle Summary KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.
CELEBRATION, Fla. , Sept. 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its president and chief executive officer, Travis C.
Toggle Summary KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital
Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales KemPharm Will Host a Conference Call and Live Audio Webcast with Slide Presentation Today, Wednesday, September 4, 2019 , at 10:00 a.m. ET CELEBRATION, Fla. , Sept.
Toggle Summary KemPharm Reports Second Quarter 2019 Results
CELEBRATION, Fla. , Aug. 13, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today reported its corporate and financial results for the quarter ended June 30, 2019 .
Toggle Summary KemPharm Reports First Quarter 2019 Results
Development & Regulatory Highlights: Completed KP415 Pre-NDA Meeting with FDA Provided Update on APADAZ ® Formulary Adoption Announced FDA Approval of sNDA for Two Additional Strengths of APADAZ Corporate & Financial Highlights: Q1 2019 net loss of $0.46 per basic and diluted share Total cash, cash